Phase I Study of Sunitinib and Irinotecan for Patients with Recurrent Malignant Glioma

BACKGROUND: We determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, when administered with irinotecan among recurrent malignant glioma patients. METHODS: For each 42-day cycle, sunitinib w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Reardon, David A., Vredenburgh, James J., Coan, April, Desjardins, Annick, Peters, Katherine B., Gururangan, Sridharan, Sathornsumetee, Sith, Rich, Jeremy N., Herndon, James E., Friedman, Henry S.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3748953/
https://ncbi.nlm.nih.gov/pubmed/21744079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0631-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares